SEC Comment Letter for Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906) — Apr 27, 2020
Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906)
Date: April 27, 2020 · CIK: 0001411906 · Accession: 0000000000-20-003564
AI Filing Summary & Sentiment
File numbers found in text: 333-237723
Letter
United States securities and exchange commission logo April 27, 2020 Michael Macaluso Chief Executive Officer Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood, CO 80112 Re:Ampio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 16, 2020 File No. 333-237723 Dear Mr. Macaluso : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leah G. Brownlee, Esq.
Show Raw Text
United States securities and exchange commission logo
April 27, 2020
Michael Macaluso
Chief Executive Officer
Ampio Pharmaceuticals, Inc.
373 Inverness Parkway, Suite 200
Englewood, CO 80112
Re:Ampio Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 16, 2020
File No. 333-237723
Dear Mr. Macaluso :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leah G. Brownlee, Esq.